TSTickerStarGet alerts

Nuwellis Reports Q3 2026 Results with 430 Basis Point Gross Margin Expansion and 24% Operating Loss Improvement

Nuwellis reported Q3 2026 net sales of $2.2 million, essentially unchanged from the prior-year quarter as the prior-year period benefited from $0.4 million in accumulated backorders. Operating loss improved 24% year-over-year to $2.1 million, driven by 430 basis points of gross margin expansion to 69.5% and a 13% reduction in operating expenses. Net loss was $2.0 million compared to net income of $0.5 million in Q3 2025, which included a $3.2 million non-cash gain from changes in fair value of warrant liabilitie...

Share this story

Key takeaways

  • Operating loss improved 24% year-over-year to $2.1 million, driven by 430 basis points of gross margin expansion and 13% reduction in operating expenses.

  • Net sales were $2.2 million in Q3 2026, essentially unchanged from the prior-year quarter, but increased 12% sequentially from Q2 2026; year-to-date net sales increased 13% to $6.6 million.

  • Pediatric segment net sales increased 20% in Q3 2026 and 26% year-to-date, remaining a significant growth driver.

  • Console unit sales increased 88% year-to-date to 32 units compared with 17 units in the prior-year period, expanding the installed base for future recurring circuit revenue.

  • Gross margin expanded to 69.5% in Q3 2026 from 65.2% in the prior-year quarter, reflecting higher average selling prices and contract manufacturing benefits.

  • Company submitted 510(k) premarket notification to FDA seeking to expand Aquadex indication to pediatric patients weighing five kilograms and above.

  • Entered into co-promotion and distribution agreement with Atrility Medical for AtriAmp postoperative cardiac rhythm monitoring device and secured exclusive U.S. distribution rights for Zorro-Flow pediatric urine collection system.

Key metrics

Net salesQ3 2026
$2.2 millionessentially unchanged (flat)
Net sales (YTD)Nine months ended September 30, 2026
$6.6 million+13%
Gross marginQ3 2026
69.5%+430 bps
Gross margin (YTD)Nine months ended September 30, 2026
71.7%+1,230 bps
Operating lossQ3 2026
$2.1 million-24% (improved)
Operating loss (YTD)Nine months ended September 30, 2026
$9.8 million+13% (worsened)
Net lossQ3 2026
$2.0 million
Net loss (YTD)Nine months ended September 30, 2026
$11.3 million-25% (improved)

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow NUWE in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert